论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Meng X, Fu R
Received 6 December 2017
Accepted for publication 7 February 2018
Published 29 March 2018 Volume 2018:11 Pages 1757—1765
DOI https://doi.org/10.2147/OTT.S159093
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Tohru Yamada
Introduction: Previous studies have found that miRNAs play a key role in drug
resistance. Multiple reports show that miRNAs act as regulators in colorectal
cancer (CRC) cells, but the role of miR-206 in CRC is still not well
understood. The current study aimed to explore the potential function of
miR-206 in 5-FU resistance.
Methods: To indentify the role of miR-206 in 5-FU resistance, the
expression of miR-206 was examined by real-time polymerase chain reaction
(RT-PCR) in 5-FU-resistant (FR) CRC (HCT116/FR and RKO/FR) and their parental
cell lines. miR-206 mimic was transfected to 5-FU-FR CRC, and the 5-FU
sensitivity was detected by MTS and flow cytometry. Using miRNA target
prediction software, we found that miR-206 could target the 3' untranslated
region (3'UTR) sequence of Bcl-2.
Results: miR-206 was found to be downregulated in 5-FU-FR CRC in comparison
with their parental cell lines, suggesting its crucial relevance for colon
cancer biology. Downregulation of miR-206 promoted drug resistance and
decreased apoptosis of parental cells, while overexpression of miR-206 promoted
drug cytotoxicity and apoptosis of HCT116/FR cells. We also identified miR-206
targeting Bcl-2 directly in CRC, which is required for miR-206 mediated-5-FU
resistance.
Conclusion: Our results show that miR-206 targets Bcl-2 to mediate chemoresistance,
proliferation, and apoptosis in CRC. This study provides a novel promising
candidate for colon cancer therapy.
Keywords: miR-206, 5-FU, resistance, Bcl-2, colorectal cancer